Advertisement

Topics

Latest "Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm" News Stories

19:44 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm" found in our extensive news archives from over 250 global news sources.

More Information about Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm for you to read. Along with our medical data and news we also list Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Clinical Trials, which are updated daily. BioPortfolio also has a large database of Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Companies for you to search.

Showing "Identifying Predictors Response Antipsychotics Using Treatment Algorithm" News Articles 1–25 of 21,000+

Tuesday 19th March 2019

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms within days Postpartum depression is the most common medical complication of childbirth, estimated to affect approximately 400,000 women annually in the U.S. Sage Therapeutics (NASDAQ: SAGE)...


MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 19.03.2019 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Shanghai, China, March 19, 2019   MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX...

An AIDS Therapy Involving Parasite Injections Was Discredited. China Is Reviving It–for Cancer

(STAT News) – American surgeon Henry Heimlich is best known for inventing a way to rescue choking victims, but a quarter-century ago, he was vilified for promoting a fringe treatment for AIDS and Lyme disease. Called malarial therapy, it involved … Read More


Landmark Ruling Sets Precedent for Parity Coverage of Mental Health and Addiction Treatment

(STAT News) – For far too long, health insurers have been treating people with mental health and substance use disorders like second-class citizens. A federal court recently ruled that this must stop. Employers and regulators, take note. The ruling came … Read More

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Recent Highlights Notice of Allowance from the United States Patent ...

SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer

DCVAC/OvCa decreased the risk of death in second line treatment of ovarian cancer by 62% Overall survival (OS) increased significantly by 13.4 months. Median Progression Free Survival (mPFS) increased by 1.8 months. SOTIO plans to initiate a global Phase III study with DCVAC/OvCa SOTIO, a biotechno...

FRESH Study Results Show Passive Leg Raise May Predict Cardiac Dysfunction in Septic Shock Patients

Data analysis leveraging Cheetah Medical technology presented at International Symposium on Intensive Care and Emergency Medicine (ISICEM) Cheetah Medical, a Massachusetts-based leader in non-invasive fluid management devices, today announced new results of a sepsis data analysis leveraging Cheetah Medical technology. The findings were presented at the...

Sage gets U.S. approval for first postpartum depression therapy

The U.S. Food and Drug Administration on Tuesday Sage Therapeutics Inc's drug for severe postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself...

Urovant Bladder Drug Hits Test Goals But Can’t Outpace Generic Rival

Urovant Sciences says its experimental drug for overactive bladder could offer advantages compared to an FDA-approved treatment marketed by Astellas Pharma. But late-stage clinical results released Tuesday raise questions whether Urovant can persuade doctors to prescribe it instead of a much cheaper generic competitor. Irvine, CA-based Urovant (NASDAQ: UROV) said Tuesday that its drug vibegron [&#...

Measles and Vaccine Hesitancy: AAP Responds

Dr Kyle Yasuda, AAP president, discusses the organization's response to anti-vaccine messages spreading on social media. Medscape Pediatrics

Breast cancer death rates continue to fall in UK

News report Breast cancer death rates will fall in the UK and across nearly all EU countries in 2019, a new study predicts. The UK is expected to record the greatest decrease out of the 6 largest EU countries, with a 13% drop predicted in 2019. It is the ninth year the annual predictions led by Professor Carlo La Vecchia, from the University of Milan, have been published. Death rates from

Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge

Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.

Physicians’ Education Resource® to Host First Annual International Congress on the Future of Neurology™

The first-of-its-kind continuing medical education-certified conference will feature 25 world-renowned experts across multiple therapeutic areas Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education (CME), will host the first annual International Congress on the Future of Neurology™ conferenc...

Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases

Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune infla...

FDA Places Partial Clinical Hold on AbbVie’s Trials Evaluating Venetoclax in Multiple Myeloma

NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax (VENCLEXTA®/VENCLYXTO®) for the investigational treatment of multiple myeloma. The partial clinical hold follows a revi...

Better Therapeutics Publishes New Study Demonstrating Rapid Reduction in Blood Pressure Among Hypertensive Adults

Mean systolic blood pressure reduction was -11.5mmHg in systolic and -5.9mmHg in diastolic, with 90% of participants lowering blood pressure from baseline. SAN FRANCISCO (PRWEB) March 19, 2019 Today, Better Therapeutics, a company developing prescription digital therapeutics for the treatment of severe cardiometabolic diseases, announced the publication of its latest peer-reviewed clinical study ...

FDA Approves Genentech’s Tecentriq Plus Chemo as First-Line Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). Th...

Science snaps: Revealing a potential new marker for aggressive prostate cancer

Science blog Scientists are constantly looking for new ways to improve cancer treatment, particularly for aggressive tumours. But spotting which cancers are aggressive when they’re first diagnosed can be tough, particularly in prostate cancer. “One of the biggest challenges so far in

SFA Therapeutics Wins Second Key U.S. Patent For Treatment of Chronic Liver Diseases

Targets Liver Cancer SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program, which utilizes microbiome-derived metabolite small molecules as drugs to modulate the body’s anti-inflammatory and immune systems (USPTO #10,231,941). As a result of this new patent, targeting Ffar...

Oral ulceration: causes and management

Patients commonly present in community pharmacy with mouth ulcers. This article describes the aetiology, presentation and treatment options for six lesion types.

Rex Medical Completes Patient Enrollment for the REVEAL Peripheral Atherectomy U.S. Trial

Rex Medical, L.P., a medical device design and development company, today announced the successful completion of enrollment in the Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization (REVEAL) IDE clinical trial. The REVEAL trial is a single arm, prospective study to evaluate the safety and effectiven...

FDA approves atezolizumab for extensive-stage small cell lung cancer

The Food and Drug Administration (FDA) approved atezolizumab in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). Approval was based on IMpower133...

Monthly Shots for HIV Within Reach

Two new trials, ATLAS and FLAIR, are being heralded as making landmark advances in HIV care and have shown noninferiority with a totally new paradigm of treatment. Medscape Medical News

Hormonal Therapy for Prostate Cancer Might Raise Depression Risk

TUESDAY, March 19, 2019 -- Hormonal treatment can help control prostate cancer but may increase a man's risk of depression, a new study by Danish researchers suggests. Male hormones, such as testosterone, are known to fuel the growth of prostate...

Global Specialty Injectable Generics Market to Surpass US$ 75.7 Billion by 2026 – Coherent Market Insights

According to Coherent Market Insights, the global specialty injectable generics market was valued at US$ 31,300 million in 2017, and is projected to exhibit a CAGR of 10.4% over the forecast period (2018 – 2026). Key Trends and Analysis of the Specialty Injectable Generics Market: Increasing prevalence of chronic diseases such as cancer...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks